Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Paradigm Biopharmaceuticals ( (AU:PAR) ) has shared an update.
Paradigm Biopharmaceuticals Ltd. announced an investor webinar to provide updates on its global phase 3 clinical trial of iPPS for knee osteoarthritis. The webinar will focus on the trial’s optimized design, regulatory alignment, and high probability of success, highlighting the company’s strategic engagement with the FDA and reliance on prior data. This development is significant for Paradigm’s operations and industry positioning as it underscores the potential effectiveness of their treatment and strengthens investor confidence.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.80 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focused on improving patient health and quality of life by developing pharmaceutical therapies. The company is currently concentrating on developing injectable pentosan polysulfate sodium (iPPS) for treating diseases characterized by inflammation, such as osteoarthritis.
Average Trading Volume: 884,612
Technical Sentiment Signal: Buy
Current Market Cap: A$166.9M
See more data about PAR stock on TipRanks’ Stock Analysis page.